Announcements Trials
Browse Landscape

Phase

Phase 2 5

Status

Completed 3Terminated 1Recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 5Thoracic 1Sarcoma 1Gastrointestinal 1Dermatologic 1

Conditions

Ovarian Neoplasms 5Melanoma 2Uterine Cervical Neoplasms 1Thymoma 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Pancreatic Neoplasms 1Glioblastoma 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Brain Neoplasms 1Astrocytoma 1

Interventions

Paclitaxel 328Carboplatin 323Bevacizumab 171Gemcitabine 106liposomal doxorubicin 104pembrolizumab 101Cyclophosphamide 96Topotecan 94olaparib 92Cisplatin 92niraparib 69Docetaxel 57Taxes 52Doxorubicin 51Drug Therapy 45fludarabine 40Filgrastim 39Nivolumab 37Magnetic Resonance Spectroscopy 34Surveys and Questionnaires 33Specimen Handling 33Etoposide 32Hyperthermic Intraperitoneal Chemotherapy 31Blood Specimen Collection 29Immunoglobulin G 27Disulfides 27Peripheral Blood Stem Cell Transplantation 26Cytoreduction Surgical Procedures 25Albumin-Bound Paclitaxel 25durvalumab 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Ovarian Neoplasms × regorafenib × Gynecologic × Clear all
NCT05113368 2025-08-21

Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer

Case Comprehensive Cancer Center

Phase 2 Recruiting
31 enrolled
Gynecologic

Ovarian Neoplasms

NCT02584465 2023-09-06

REGOVAR

ARCAGY/ GINECO GROUP

Phase 2 Completed
68 enrolled
Gynecologic

Ovarian Neoplasms

NCT02307500 2022-09-10

RESOUND

Istituto Clinico Humanitas

Phase 2 Completed
82 enrolled
DermatologicGastrointestinalGynecologicSarcomaThoracic

Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Thymoma

NCT02736305 2022-06-13

Use of Regorafenib in Recurrent Epithelial Ovarian Cancer

National Cancer Centre, Singapore

Phase 2 Completed
21 enrolled
Gynecologic

Ovarian Neoplasms

NCT02278783 2017-10-06

Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer

University of Utah

Phase 2 Terminated
1 enrolled 5 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡